Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02683330
Other study ID # PSYETH (S/F) 15/16 112
Secondary ID Innovation grant
Status Completed
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date March 2017

Study information

Verified date January 2019
Source City, University of London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Psychological difficulties, especially depression and anxiety are the most prevalent non-motor symptoms in Parkinson's Disease (PD). Pharmacological treatments are not as effective in PD. Mindfulness courses have received increased popularity and recognition as an effective way to manage emotional states, and there is ever growing findings of the effectiveness of mindfulness courses for people with long-term medical conditions. Two small pilot studies have indicated that mindfulness courses can be helpful for people with PD in improving symptoms of depression, language functioning and motor symptoms. The investigators propose to deliver these courses remotely, through Skype video conferences, to make it more accessible for people with mobility limitations and people who live in rural areas.


Description:

This study will employ a mixed-methods design, with an experimental randomised control trial followed by a qualitative design. Sixty participants will be randomly assigned to the 8-week mindfulness course (n=30) or a wait-list control group (n=30). Block randomisation will be used and the randomisation scheme will be generated using the randomisation.com website. One-hour sessions will be delivered to groups of 5 people using Skype video-conferencing. As this is a pilot study analyses will largely be descriptive. Further, inferential analyses using mixed modelling will be conducted by intention-to-treat. At the end of the intervention, the investigators will interview the participants of the mindfulness group about their experiences of the course.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 2017
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- be diagnosed with PD according to PD Brain Bank criteria by a neurologist or geriatrician

- have a computer and internet access at home, since the course will be delivered via Skype

- be able to communicate in English fluently

- be stabilised on mood altering medication and/or Parkinson's medication for a month

Exclusion Criteria:

- have severe cognitive impairment that would make participation in the mindfulness sessions and home practice of mindful meditation problematic or distressing. This will be assessed using the Telephone Interview for Cognitive Status-Modified (TICS-M, Brandt et al., 1993).

- have severe psychiatric conditions (e.g. psychosis, drug/ alcohol addiction) that can potentially risk failure in the treatment or limit participation in the course

- have severe hearing impairment

- are currently participating in other psychological therapies

- have prior formal training in mindfulness methods or current meditation practice

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindfulness-based intervention (MBI)
MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.

Locations

Country Name City State
United Kingdom City University London London

Sponsors (1)

Lead Sponsor Collaborator
City, University of London

Country where clinical trial is conducted

United Kingdom, 

References & Publications (3)

Brandt J, Welsh KA, Breitner JC, Folstein MF, Helms M, Christian JC. Hereditary influences on cognitive functioning in older men. A study of 4000 twin pairs. Arch Neurol. 1993 Jun;50(6):599-603. — View Citation

Cash, T. V., et al. (2015). Pilot Study of a Mindfulness-Based Group Intervention for Individuals with Parkinson's Disease and Their Caregivers. Mindfulness 1-11.

Pickut B, Vanneste S, Hirsch MA, Van Hecke W, Kerckhofs E, Mariën P, Parizel PM, Crosiers D, Cras P. Mindfulness Training among Individuals with Parkinson's Disease: Neurobehavioral Effects. Parkinsons Dis. 2015;2015:816404. doi: 10.1155/2015/816404. Epub 2015 May 26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Self-Compassion Scale (SCS) Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20)
Other Philadelphia Mindfulness Scale (PHLMS) Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20)
Other Experiences Questionnaire (EQ) Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20)
Other Acceptance Action Questionnaire (AAQ-II) Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20)
Other Subjective Well-Being questionnaire (SWB) Baseline, Post-intervention (week 8) and Follow-up (week 20)
Other EuroQol Five-Dimensional questionnaire (EQ-5D-3L) Baseline, Post-intervention (week 8) and Follow-up (week 20)
Other Visual Analogue Scale (VAS) Baseline, Post-intervention (week 8) and Follow-up (week 20)
Other ICEpop CAPability measure for Adults (ICECAP-A) Baseline, Post-intervention (week 8) and Follow-up (week 20)
Other Adult Social Care Outcomes Toolkit (ASCOT) Baseline, Post-intervention (week 8) and Follow-up (week 20)
Primary Change from baseline Hospital Anxiety and Depression Scale (HADS) at 4, 8 and 20 weeks HADS also assessed at Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) time points. Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20).
Secondary Parkinson's Disease Activities of Daily Living Scale (PADLS) Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20)
Secondary Brief Pain Inventory (BPI) Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20)
Secondary Fatigue Severity Scale (FSS) Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20)
Secondary Insomnia Severity Index (ISI) Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20)
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A
Completed NCT02939391 - A Study of KW-6356 in Subjects With Early Parkinson's Disease Phase 2